Hope you all had a great ThanksGiving ! Specially after our last alert HDRE delivered easy 100% GREEN !
Today, I have something special for you. As you are aware my long term plays PLPL and NVLX have rocked the party for all our members. So, here is my another biotech play !
International Stem Cell Corporation (ISCO).
http://www.internationalstemcell.com/
International Stem Cell Corporation is a biotechnology company that has developed a promising new stem cell technology based on a natural process called parthenogenesis. In parthenogenesis, stem cells are derived from unfertilized human eggs. The technique can create what's called HLA homozygous stem cells, which are stem cells meaning that are much less likely to be rejected. This is a property called histocompatibility.
Over the past few weeks, ISCO has gained significant investor enthusiasm. Have you seen their latest Q3 ? Simply WOW !
Q3 2013 Highlights:
Record revenues of $1.67 million, a 41% increase over the corresponding period of 2012. Lifeline Skin Care sales up 54% and Lifeline Cell Technology sales up 30%. Gross margin stable at 73%.
Net cash used in operating cash flows (which exclude capital expenditures and patent costs), reduced to approximately $0.47 million per month compared to $0.57 million per month the corresponding period of 2012.
Entered into a clinical research agreement with Duke University for the evaluation of ISCO's stem cell-derived neural stem cells for the treatment of Parkinson's disease. Prof. Mark Stacy, M.D., Vice Dean for Clinical Research, Neurology at Duke University School of Medicine and an internationally recognized leader in the field of Movement Disorders, will be the principal investigator.
Convened a key opinion leader meeting bringing together leading experts from throughout North America in the field of cell therapy and movement disorders to obtain feedback and guidance for the IND submission in 2014 for our stem cell-derived neural stem cells for the treatment of Parkinson's disease.
Presented the results of the first primate study, carried out in collaboration with the Sanford Burnham Institute of Regenerative Medical, examining the benefits of implanting neural stem cells into primates with chemically-induced parkinsonian symptoms, at the American Neurological Association 2013 Annual Meeting.
Obtained gross proceeds of $3.00 million through a public offering, to be used to fund R&D programs.
I am sure you must be very impressed with those numbers ! So, its time to begin your DD !